Chemoinformaics analysis of 2-Oxoalantolactone
| Molecular Weight | 246.306 | nRot | 0 |
| Heavy Atom Molecular Weight | 228.162 | nRig | 18 |
| Exact Molecular Weight | 246.126 | nRing | 3 |
| Solubility: LogS | -1.828 | nHRing | 1 |
| Solubility: LogP | 1.759 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 36 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 39.4583 |
| nHD | 0 | BPOL | 21.5297 |
| QED | 0.374 |
| Synth | 4.746 |
| Natural Product Likeliness | 2.901 |
| NR-PPAR-gamma | 0.207 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.003 |
| HIA | 0.015 |
| CACO-2 | -4.818 |
| MDCK | 0.0000423 |
| BBB | 0.75 |
| PPB | 0.603737 |
| VDSS | 0.972 |
| FU | 0.581541 |
| CYP1A2-inh | 0.199 |
| CYP1A2-sub | 0.483 |
| CYP2c19-inh | 0.184 |
| CYP2c19-sub | 0.706 |
| CYP2c9-inh | 0.188 |
| CYP2c9-sub | 0.074 |
| CYP2d6-inh | 0.022 |
| CYP2d6-sub | 0.115 |
| CYP3a4-inh | 0.705 |
| CYP3a4-sub | 0.246 |
| CL | 11.728 |
| T12 | 0.436 |
| hERG | 0.003 |
| Ames | 0.452 |
| ROA | 0.807 |
| SkinSen | 0.557 |
| Carcinogencity | 0.837 |
| EI | 0.055 |
| Respiratory | 0.987 |
| NR-Aromatase | 0.851 |
| Antiviral | Yes |
| Prediction | 0.787823 |